Anita Midha

Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer

M. Ratcliffe, Alan Sharpe, Anita Midha et al. · Clinical Cancer Research · 2017 · 303 citations

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Marlon C. Rebelatto, Anita Midha, Amita Mistry et al. · Diagnostic Pathology · 2016 · 177 citations · Full text

Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy

William McCoull, Andrew Bailey, Peter Barton et al. · Journal of Medicinal Chemistry · 2017 · 33 citations · Full text

Molecular Pharmacology, Gpr120 Agonists, Gpr120 Potency +12

Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients.

Marlon C. Rebelatto, Amita Mistry, Costi Sabalos et al. · Journal of Clinical Oncology · 2015 · 29 citations

Immunology, Pathology, Immunotherapeutics +21

PD-L1 expression in advanced NSCLC: Primary lesions versus metastatic sites and impact of sample age.

Anita Midha, Alan Sharpe, Marietta Scott et al. · Journal of Clinical Oncology · 2016 · 28 citations

Sample Age, Immunology, Immunoediting +20